Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Zai Lab Acquires China Rights to Novel Antibiotic from Paratek

publication date: Apr 24, 2017
Shanghai's Zai Lab acquired Greater China rights to omadacycline, an antibiotic for drug-resistant infections, from Paratek Pharma of Boston. Zai will make a $7.5 million upfront payment plus pay development, regulatory and commercial milestones and royalties. The antibiotic is Zai Lab's eighth in-licensed product: the company is developing four cancer candidates, two anti-inflammatory products, a treatment for eczema and now an antibiotic. Zai also recently partnered with GE Healthcare to build a biomanufacturing plant in Suzhou. More details...

Stock Symbol: (NSDQ: PRTK)

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital